Jazz Pharmaceuticals Enters a ~$1.03B Licensing Deal with Saniona for SAN2355

Shots: Jazz Pharmaceuticals has entered into a global license agreement with Saniona to develop SAN2355 for epilepsy & other potential indications As per the deal, Jazz will lead & fund development, regulatory filings, & global commercialization in exchange for $42.5M upfront, ~$192.5M in development & regulatory milestones (incl. $7.5M at P-I initiation), ~$800M in commercial milestones, &…

ByRidhi RastogiAugust 21, 2025

PetPace Launches Epilepsy Insights Module for Canine Seizure Monitoring

Shots: PetPace has launched an Epilepsy Insights module to deliver low-latency, data-driven insights on epileptic events in dogs; available for beta testing in dogs with a confirmed epilepsy diagnosis The Epilepsy Insights module is powered by the PetPace smart collar & uses AI as well as ML to manage canine epilepsy through continuous monitoring & automated…

ByRidhi RastogiAugust 14, 2025

Aquestive Therapeutics’ Libervan Buccal Film Receives the US FDA’s Approval to Treat Seizure Activity

Shots: Aquestive’s Libervant buccal film (oral, 5mg, 7.5mg, 10mg, 12.5mg & 15mg) received the US FDA’s approval as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures), distinct from the usual pattern in epilepsy patients (2-5yrs.) The company further provided an update on Anaphylm (epinephrine) sublingual film,…

ByDipanshu DixitApril 29, 2024

Jazz Pharmaceuticals Enters a ~$1.03B Licensing Deal with Saniona for SAN2355

PetPace Launches Epilepsy Insights Module for Canine Seizure Monitoring

Aquestive Therapeutics’ Libervan Buccal Film Receives the US FDA’s Approval to Treat Seizure Activity

Contact US

OUR INFORMATION

FOLLOW US